Can a menin inhibitor tame myelofibrosis when standard drugs fall short?

NCT ID NCT07734077

Not yet recruiting Disease control Sponsor: John Mascarenhas Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor. The goal is to see if this approach can improve response rates and manage the disease better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: revumenib, a menin inhibitor, tested alone or with JAK inhibitors (ruxolitinib, fedratinib, or momelotinib)
What this could lead to: If successful, this could offer a new treatment option for myelofibrosis patients who have not responded well to JAK inhibitors alone.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. Side effects like low blood cell counts are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

Contacts and locations

Locations

Icahn School of Medicine at the Mount Sinai Hospital

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.